The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Trump shared the anecdote as he signed an order Monday intended to drastically reduce the price Americans pay for ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

Commerce officials approved an incentives package worth up to $13.1 million for the company, which plans to build a $700 million plant in the Wake County town. It's the latest drugmaker to target the ...

Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and therefore less hungry.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Many economists expect muted U.S. economic growth in the coming quarters, and the first quarter's negative GDP growth makes a mild recession a real possibility. It may become difficult for ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive strategy.

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.